NEW YORK – Cancer early detection firm Singlera is pushing forward to commercialize a DNA-methylation-based assay called PanSeer with an immediate focus on colorectal cancer, but potential to expand that to a more pan-cancer setting in the future.
The company, which was founded in 2014 and has offices in California and Shanghai, reached a milestone this month with the publication of promising data from a study of the assay's performance in a longitudinal cohort of cancer-free individuals — the intended use population for this type of screening test.